AI - Skin Analytics

Skin Analytics achieves Class IIa UKCA Mark for DERM. The UK’s first and only Class IIa certified AI dermatology device

April 19, 2022

Now a Class IIa medical device, DERM, uses machine learning algorithms to recognise the most common malignant, pre-malignant and benign skin lesions, including melanoma – the fifth most common cancer in the UK. Using a decade’s worth of research and development on skin lesions, it is designed to accelerate patient diagnosis and relieve pressure on the healthcare system.

Discussing the systematic review of skin cancer datasets in The Lancet: Skin Analytics response.

November 16, 2021

We were delighted to see research into the publicly available skin cancer datasets many use to train AI systems to assess skin cancer published in

Skin Analytics Receives NHSX Award for AI-Based Skin Cancer Tool

July 14, 2021

Deployment of unique diagnosis aid to be boosted across the NHS Currently deployed in University Hospitals Birmingham and Mid and South Essex Health & Care

Google’s move into skin cancer analysis is great news for patients and Skin Analytics

June 3, 2021

Google’s announcement of the culmination of three years of work and a subsequent move into skin disease analysis at their developer conference earlier this week has led

Deploying Safe and Effective AI in Skin Cancer Pathways

January 27, 2021

26 January 2021 In December, the British Association of Dermatologist (BAD) President’s Bulletin included an article from Dr Rubeta Matin with an update from the

Skin Analytics response to NHS AI Code of Conduct

March 3, 2020

In July 2019 the Department of Health and Social Care and NHS England published a new code of conduct for the use of digital technology

Response: BMJ article: B2C apps not up to standard.

February 13, 2020

In February 2020, skin cancer researchers released a paper calling into question…

New data shows DERM, our AI skin cancer diagnosis tool, could be as accurate as clinical specialist

October 17, 2019

The prospective, diagnostic trial saw DERM, our AI platform, correctly identify all malignant lesions (100% sensitivity) with an average AUROC of 95.8% with 65% specificity versus 70% specificity and a 77% AUROC score demonstrated by the clinical experts. DERM, a CE marked medical device, was developed as a tool to aid clinicians in identifying 11 common skin lesion types, including melanoma.

AI for Skin Cancer… But we are NOT a technology business

May 30, 2019

It is true, we are not a technology company… Perhaps I should explain? When we started our journey to bring better access to high quality

Technical Partnerships

January 21, 2019

At Skin Analytics we have found that part of the skill required to successfully develop AI as a medical device is to know when to

News